Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.28 Million USD | 116.19% |
| 2022 | -26.42 Million USD | 83.37% |
| 2021 | -158.88 Million USD | -29.76% |
| 2020 | -122.44 Million USD | 44.8% |
| 2019 | -221.8 Million USD | -697.62% |
| 2018 | -27.8 Million USD | -24.67% |
| 2017 | -22.3 Million USD | 73.01% |
| 2016 | -82.63 Million USD | -2.71% |
| 2015 | -80.45 Million USD | 38.81% |
| 2014 | -131.48 Million USD | -682.18% |
| 2013 | -16.81 Million USD | -1515.44% |
| 2012 | -1.04 Million USD | 84.92% |
| 2011 | -6.9 Million USD | -8.72% |
| 2010 | -6.34 Million USD | -699.7% |
| 2009 | -793.69 Thousand USD | 90.72% |
| 2008 | -8.55 Million USD | 64.53% |
| 2007 | -24.12 Million USD | 10.07% |
| 2006 | -26.82 Million USD | -19.38% |
| 2005 | -22.46 Million USD | -162.69% |
| 2004 | -8.55 Million USD | -531.06% |
| 2003 | -1.35 Million USD | -320.37% |
| 2002 | 615 Thousand USD | 10.07% |
| 2001 | 558.72 Thousand USD | -0.41% |
| 2000 | 561.04 Thousand USD | -0.68% |
| 1999 | 564.87 Thousand USD | -57.7% |
| 1998 | 1.33 Million USD | 30.56% |
| 1997 | 1.02 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 384.72 Million USD | 41.36% |
| 2024 Q1 | 60.36 Million USD | 1310.35% |
| 2024 Q2 | 272.15 Million USD | 350.86% |
| 2023 Q3 | -22.6 Million USD | 56.69% |
| 2023 Q2 | -52.17 Million USD | 56.56% |
| 2023 FY | 4.28 Million USD | 116.19% |
| 2023 Q1 | -120.11 Million USD | -354.48% |
| 2023 Q4 | 4.28 Million USD | 118.94% |
| 2022 Q1 | -66.27 Million USD | 58.29% |
| 2022 FY | -26.42 Million USD | 83.37% |
| 2022 Q4 | -26.42 Million USD | 54.69% |
| 2022 Q3 | -58.32 Million USD | 4.07% |
| 2022 Q2 | -60.8 Million USD | 8.26% |
| 2021 Q3 | -301.83 Million USD | 13.41% |
| 2021 Q4 | -158.88 Million USD | 47.36% |
| 2021 Q2 | -348.57 Million USD | -192.79% |
| 2021 FY | -158.88 Million USD | -29.76% |
| 2021 Q1 | -119.05 Million USD | 2.77% |
| 2020 Q3 | -197.95 Million USD | 18.13% |
| 2020 FY | -122.44 Million USD | 44.8% |
| 2020 Q1 | -446.19 Million USD | -101.17% |
| 2020 Q2 | -241.78 Million USD | 45.81% |
| 2020 Q4 | -122.44 Million USD | 38.14% |
| 2019 Q3 | -188.33 Million USD | -16.51% |
| 2019 Q4 | -221.8 Million USD | -17.77% |
| 2019 Q1 | -189.77 Million USD | -582.44% |
| 2019 FY | -221.8 Million USD | -697.62% |
| 2019 Q2 | -161.63 Million USD | 14.82% |
| 2018 Q2 | -67.37 Million USD | -644.58% |
| 2018 FY | -27.8 Million USD | -24.67% |
| 2018 Q3 | -25.61 Million USD | 61.98% |
| 2018 Q4 | -27.8 Million USD | -8.55% |
| 2018 Q1 | -9.04 Million USD | 59.43% |
| 2017 Q4 | -22.3 Million USD | 37.69% |
| 2017 FY | -22.3 Million USD | 73.01% |
| 2017 Q3 | -35.79 Million USD | 39.41% |
| 2017 Q2 | -59.08 Million USD | 40.57% |
| 2017 Q1 | -99.42 Million USD | -20.31% |
| 2016 Q2 | -49.65 Million USD | 19.22% |
| 2016 FY | -82.63 Million USD | -2.71% |
| 2016 Q4 | -82.63 Million USD | -105.09% |
| 2016 Q1 | -61.46 Million USD | 23.61% |
| 2016 Q3 | -40.29 Million USD | 18.85% |
| 2015 Q3 | -86.44 Million USD | 9.56% |
| 2015 FY | -80.45 Million USD | 38.81% |
| 2015 Q1 | -103.07 Million USD | 21.61% |
| 2015 Q4 | -80.45 Million USD | 6.92% |
| 2015 Q2 | -95.58 Million USD | 7.27% |
| 2014 Q3 | -137.27 Million USD | 2.45% |
| 2014 Q4 | -131.48 Million USD | 4.22% |
| 2014 FY | -131.48 Million USD | -682.18% |
| 2014 Q1 | -57.43 Million USD | -241.67% |
| 2014 Q2 | -140.71 Million USD | -145.0% |
| 2013 FY | -16.81 Million USD | -1515.44% |
| 2013 Q1 | -501.54 Thousand USD | 51.8% |
| 2013 Q3 | -26.71 Million USD | -2591.32% |
| 2013 Q4 | -16.81 Million USD | 37.07% |
| 2013 Q2 | -992.58 Thousand USD | -97.91% |
| 2012 FY | -1.04 Million USD | 84.92% |
| 2012 Q3 | 60.83 Thousand USD | 104.89% |
| 2012 Q1 | -4.41 Million USD | 36.0% |
| 2012 Q4 | -1.04 Million USD | -1810.63% |
| 2012 Q2 | -1.24 Million USD | 71.82% |
| 2011 Q2 | -4.26 Million USD | 14.03% |
| 2011 Q4 | -6.9 Million USD | -83.75% |
| 2011 FY | -6.9 Million USD | -8.72% |
| 2011 Q1 | -4.96 Million USD | 21.75% |
| 2011 Q3 | -3.75 Million USD | 12.05% |
| 2010 Q1 | -2.79 Million USD | -252.28% |
| 2010 FY | -6.34 Million USD | -699.7% |
| 2010 Q4 | -6.34 Million USD | 24.52% |
| 2010 Q3 | -8.4 Million USD | -368.02% |
| 2010 Q2 | -1.79 Million USD | 35.74% |
| 2009 Q4 | -793.69 Thousand USD | -67.47% |
| 2009 Q3 | -473.93 Thousand USD | -578.89% |
| 2009 Q1 | -3.77 Million USD | 55.82% |
| 2009 FY | -793.69 Thousand USD | 90.72% |
| 2009 Q2 | 98.96 Thousand USD | 102.62% |
| 2008 Q1 | -25.42 Million USD | -5.41% |
| 2008 Q2 | -19.52 Million USD | 23.21% |
| 2008 Q3 | -13.82 Million USD | 29.19% |
| 2008 Q4 | -8.55 Million USD | 38.1% |
| 2008 FY | -8.55 Million USD | 64.53% |
| 2007 Q1 | -28.26 Million USD | -5.39% |
| 2007 Q3 | -3.42 Million USD | 84.15% |
| 2007 Q4 | -24.12 Million USD | -605.0% |
| 2007 FY | -24.12 Million USD | 10.07% |
| 2007 Q2 | -21.59 Million USD | 23.61% |
| 2006 FY | -26.82 Million USD | -19.38% |
| 2006 Q1 | -19.1 Million USD | 14.96% |
| 2006 Q4 | -26.82 Million USD | -60.72% |
| 2006 Q3 | -16.68 Million USD | -0.62% |
| 2006 Q2 | -16.58 Million USD | 13.19% |
| 2005 Q1 | -6.76 Million USD | 20.89% |
| 2005 FY | -22.46 Million USD | -162.69% |
| 2005 Q4 | -22.46 Million USD | 10.55% |
| 2005 Q3 | -25.11 Million USD | -169.78% |
| 2005 Q2 | -9.31 Million USD | -37.61% |
| 2004 Q1 | -1.42 Million USD | -5.41% |
| 2004 Q3 | -9.83 Million USD | 4.75% |
| 2004 FY | -8.55 Million USD | -531.06% |
| 2004 Q4 | -8.55 Million USD | 13.08% |
| 2004 Q2 | -10.33 Million USD | -623.16% |
| 2003 Q4 | -1.35 Million USD | -317.0% |
| 2003 FY | -1.35 Million USD | -320.37% |
| 2003 Q1 | 628.04 Thousand USD | 2.12% |
| 2003 Q2 | 630.09 Thousand USD | 0.33% |
| 2003 Q3 | 624.54 Thousand USD | -0.88% |
| 2002 FY | 615 Thousand USD | 10.07% |
| 2002 Q4 | 615 Thousand USD | 6.36% |
| 2002 Q2 | 533.61 Thousand USD | -4.02% |
| 2002 Q1 | 555.99 Thousand USD | -0.49% |
| 2002 Q3 | 578.21 Thousand USD | 8.36% |
| 2001 FY | 558.72 Thousand USD | -0.41% |
| 2001 Q1 | 562.24 Thousand USD | 0.21% |
| 2001 Q2 | 561.75 Thousand USD | -0.09% |
| 2001 Q4 | 558.72 Thousand USD | -0.14% |
| 2001 Q3 | 559.5 Thousand USD | -0.4% |
| 2000 Q3 | 562.95 Thousand USD | -0.05% |
| 2000 Q4 | 561.04 Thousand USD | -0.34% |
| 2000 FY | 561.04 Thousand USD | -0.68% |
| 2000 Q2 | 563.24 Thousand USD | -0.2% |
| 2000 Q1 | 564.37 Thousand USD | -5.94% |
| 1999 Q2 | 1.1 Million USD | 0.0% |
| 1999 Q4 | 600 Thousand USD | 0.0% |
| 1999 Q3 | 600 Thousand USD | -45.45% |
| 1999 FY | 564.87 Thousand USD | -57.7% |
| 1998 Q2 | 1 Million USD | 0.0% |
| 1998 Q3 | 1.1 Million USD | 10.0% |
| 1998 Q4 | 1.1 Million USD | 0.0% |
| 1998 FY | 1.33 Million USD | 30.56% |
| 1997 FY | 1.02 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 97.354% |
| Codexis, Inc. | -43.27 Million USD | 109.891% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 105.234% |
| Organovo Holdings, Inc. | -1.5 Million USD | 384.008% |